Digital Health Investment Weekly Report Vol.157: Global Funding Highlights and Industry Insights
EverBridge
Global Healthcare Technology Platform
Supira Medical
Medical Auxiliary Equipment Developer
Character Biosciences
Precision Medical Solutions Developer for Genetic Diseases
Ampersand Biomedicines
Next-Generation Modular Drug Developer
01 Global Digital Health Investment and Financing Overview
Global Medical Technology Platform EverBridge Raises Over 1 Billion Yuan in Series A Financing
On March 25, EverBridge, a global medical technology platform, secured over 1 billion yuan in its Series A round of financing, led by CBC Group with participation from Beijing Medical and Health Industry Investment Fund and Beishang Capital. This funding will support EverBridge in accelerating product development and commercialization strategies, further solidifying its leading position in innovative treatments for high-incidence chronic diseases.
Supira Medical, a Developer of Percutaneous Ventricular Assist Devices, Secures $120 Million in Series E Financing
On March 26, Supira Medical, a developer of percutaneous ventricular assist devices, secured $120 million in Series E funding led by Novo Holdings and the Qatar Investment Authority, with participation from other strategic and existing investors. The funds will be used to expand Supira's clinical programs in high-risk percutaneous coronary interventions and cardiogenic shock, including the SUPPORT II U.S. pivotal study aimed at seeking FDA PMA approval.
Precision Medicine Platform Character Biosciences Secures $93 Million in Series B Financing
On March 35, precision medicine platform Character Biosciences secured a $93 million Series B financing round. The round was co-led by new investors aMoon and Luma Group, with participation from Bausch+Lomb, Jefferson Life Sciences, and existing investors Innovation Endeavors, Catalio Capital Management, S32, and KdT Ventures. The funds will enable AMD's lead candidates, CTX114 and CTX203, to enter clinical trials next year.
Biopharmaceutical Company Tempero Bio, Inc. Secures $70 Million in Series B Financing
On March 24, biopharmaceutical company Tempero Bio, Inc. secured a $70 million Series B financing round led by 8VC, with participation from Aditum Bio, Khosla Ventures, and other investors. The proceeds will be used to advance two Phase 2 clinical trials of TMP-301 for alcohol use disorder and cocaine use disorder, as well as Phase 3 support activities and preclinical studies for other indications and formulations.
Next-Generation Modular Drug Developer Ampersand Biomedicines Secures $65 Million in Series B Financing
On March 19, Ampersand Biomedicines, a next-generation modular drug developer, secured $65 million in Series B funding, invested by Flagship Pioneering and Eli Lilly & Company. The Series B funding will drive the ongoing development of its computation-driven Address, Navigate, Determine (AND)™ platform to program AND Body™ Therapeutics, a new category of intelligent biopharmaceuticals.
Primary Care Clinical Platform Developer Navina Secures $55 Million in Series C Funding
On March 25, Navina, a developer of primary care clinical platforms, secured $55 million in Series C funding led by Goldman Sachs. The company offers an AI co-pilot that collects and analyzes patient data from EHRs and various other sources to facilitate physicians' participation in value-based care models.
Cardiac Dimensions, a developer of novel interventional tools for mitral regurgitation, secures $53 million in Series E financing
On March 20, Cardiac Dimensions, a developer of novel interventional tools for mitral regurgitation, secured $53 million in Series E funding led by Ally Bridge Group, with participation from new investor Claret Capital Partners and existing investor Hostplus, among others. The funds will support the completion of the pivotal U.S. EMPOWER Trial and the ongoing commercialization of the innovative Carillon Mitral Contour System.
Medical Imaging Diagnostics Provider Proscia Secures $50 Million in Financing
On March 19, medical imaging diagnostics provider Proscia secured $50 million in funding, led by Insight Partners, AI Capital Partners, and Triangle Peak Partners. The funds will be used to further expand the adoption of the Proscia platform, integrate more AI functionalities, and leverage strategic OEM partnerships with industry giants such as Agilent Technologies and Siemens Healthineers.
Biopharmaceutical Outsourcing Service Provider Wheeler Bio Secures $35 Million Series A Financing
On March 20, biopharmaceutical outsourcing service provider Wheeler Bio secured $35 million in Series A funding, led by Alloy Therapeutics and Echo Investment Capital, with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises. This investment accelerates Wheeler Bio's growth and expands its capacity to provide high-quality CMC services for antibody-based therapies.
Automated Patient Monitoring Platform Inspiren Secures $35 Million Series A Funding
On March 20, automated patient monitoring platform Inspiren secured $35 million in Series A funding, led by Avenir with participation from Primary Venture Partners, Story Ventures, Third Prime, and Studio VC. The funds will support the development of Inspiren's clinical advisory services and internal teams, as well as further expand its senior living ecosystem.
Sibel Health, a Developer of Health Data Monitoring Products, Secures $30 Million in Series C Funding
On March 20, Sibel Health, a developer of health data monitoring products, secured $30 million in Series C funding, led by the Steele Foundation for Hope and Dräger. Sibel Health is an award-winning medical technology company with a mission to provide better health data for everyone.
Cardiovascular Solutions Provider T45 Labs Secures $25 Million in Financing
On March 19, cardiovascular solutions provider T45 Labs secured $25 million in funding. The oversubscribed fund indicates investors' strong confidence in T45 Labs' mission to deliver groundbreaking cardiovascular technologies and drive meaningful advancements in patient care. This round of financing will continue to advance the milestones of T45 Labs' growing portfolio of cardiovascular medical device companies.
AI Software Solutions Developer Brainomix Secures £14 Million in Series C Funding
On March 20, Brainomix, a developer of AI software solutions, secured £14 million in Series C funding, led by Parkwalk Advisors, Boehringer Ingelheim Venture Fund, along with new investors Hostplus and LifeSci Capital. This new investment will enable Brainomix to accelerate its commercial expansion in the U.S. and support the advancement of its AI technology portfolio into new areas, promoting faster diagnosis and increasing access to life-saving treatments.
Hisky Medical, a developer of non-invasive liver fibrosis detection devices, secures over RMB 100 million in Series D funding
On March 24, Hisky Medical, a developer of non-invasive liver fibrosis detection equipment, secured over RMB100 million in its D-round financing. This round of investment was led by Sunlight Ronghui Capital, with co-investment from Hunan Pharmaceutical Development Fund and Guangzhou Bio Island Life Science Innovation and Entrepreneurship Investment Fund. Hisky Medical is a rare high-quality enterprise in China's high-end medical equipment sector. Its innovative technologies and products have been applied and recognized by thousands of medical institutions worldwide. It is also a successful case of industry-academia collaboration from Tsinghua University.
Self-Medication Injection System Solution Provider Wanhai Medical Secures 100 Million Yuan in Financing
On March 25, Wanhai Medical, a provider of self-medication injection system solutions, secured 100 million yuan in financing exclusively invested by IDG Capital, with One Capital serving as the exclusive financial advisor. This round of financing will support Wanhai Medical to further expand its annual production capacity by 310 million units on the basis of the current 90 million units, forming a total annual production capacity of 400 million units in an automated and intelligent injection pen production base, further solidifying its leading position in the global injection pen market.
Fuwor Pharma Completes New Round of Financing Worth Hundreds of Millions
On March 19, Foyou Pharmaceuticals, an innovative oncology drug developer, completed a new round of financing worth hundreds of millions of yuan. The round was led by Wuhan Optics Valley Science and Technology Innovation Industry Investment Fund under Wuhan Hi-Tech Group, collectively driving innovation-driven pharmaceutical companies to overcome technical barriers and accelerate the research, development, and commercialization of domestically produced anti-cancer drugs in China.
Exoskeleton Robot Developer Chendu Technology Secures Nearly RMB100 Million in Series B Financing
On March 27, Exoskeleton robot developer Chengtian Technology secured nearly RMB 100 million in its Series B round of financing, led by Xichuang Investment, with Haoyue Capital serving as the exclusive financial advisor. The funds will be primarily allocated to the R&D iteration of embodied intelligence exoskeleton technology, the development and registration of brain-computer interface new products, the expansion of production bases, and the global market expansion. This aims to further promote the application of embodied intelligence exoskeleton wearable robots in rehabilitation, elderly care, and consumer markets, accelerate the expansion of domestic and overseas channel networks, and build a globally leading exoskeleton technology enterprise.
Insilico Medicine Collaborates with Mabwell to Develop AI-Powered ADC Innovative Drugs
On March 27, Insilico Medicine announced a strategic partnership with Mabwell Biotherapeutics. The collaboration will leverage the technical strengths of both companies in ADC research and AI to drive innovation in ADC drug development through AI. Together, they will develop next-generation toxin payloads with novel biological mechanisms, innovative structures, and pharmacological activity, enhancing ADC innovation efficiency and supporting the upgrading and iteration of AI platforms. Through this partnership, both parties will utilize AI technology to improve drug discovery efficiency and address unmet clinical needs worldwide.
NVIDIA Collaborates with GE Healthcare to Advance Autonomous Diagnostic Imaging Development by Introducing Physics AI
On March 19, NVIDIA and GE Healthcare announced a deepened collaboration to jointly advance the development of autonomous diagnostic imaging. This partnership will help GE Healthcare achieve breakthroughs in the field of autonomous imaging technology, improving the efficiency and accessibility of diagnostic imaging. The two parties will focus on developing autonomous X-ray technology and ultrasound applications, accelerating the R&D process by introducing the NVIDIA Isaac™ for Healthcare medical device simulation platform, enabling automated operations in complex workflows such as patient positioning, scanning, and quality inspection in imaging systems. Leveraging NVIDIA’s AI technology, this collaboration will promote the intelligent development of medical imaging systems and enhance the patient care experience.
Smart Eye and Huawei Jointly Release Medical Smart All-in-One Machine
On March 21, Wisdom Eye, in collaboration with Huawei, released the full-stack Chinese-produced medical intelligent all-in-one machine "Bianshi + DeepSeek Dual-Engine Medical Intelligent All-in-One Machine," aiming to promote the development of medical intelligence. This all-in-one machine is built on the Ascend AI chip to provide computational power, innovatively integrating "AI middleware, digital human, Bianshi large model, and DeepSeek" seamlessly, achieving full-link localization from underlying hardware, middleware to upper-layer applications. The product covers dozens of intelligent healthcare scenarios including smart medical insurance review, clinical decision support, intelligent triage, medical record generation, health consultation, and chronic disease management.
Ophthalmic Pharmaceuticals and Medical Devices Manufacturer Alcon Acquires Aurion Biotech
On March 26, ophthalmic pharmaceuticals and medical device manufacturer Alcon acquired Aurion Biotech, a clinical-stage company developing advanced cell therapies for eye diseases. Aurion will operate as an independent company under Alcon’s full support to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 by the second half of 2025, targeting corneal edema secondary to corneal endothelial disease.
Healthcare IT Solutions Provider VisiQuate Acquires Rotera
On March 25, healthcare IT solutions provider VisiQuate acquired Rotera to enhance AI-driven healthcare automation. This strategic acquisition strengthens VisiQuate's Machina Automation Studio, delivering next-generation Agent AI to help healthcare organizations optimize financial operations and reduce manual intervention.
Next-Generation Technology Platform EnrollHere Acquires MyMedicareBot
On March 25, the next-generation technology platform EnrollHere acquired MyMedicareBot, creating the first fully integrated end-to-end enrollment ecosystem in the Medicare industry — streamlining the entire sales process from lead generation to policy issuance. This strategic acquisition solidifies EnrollHere's position as the industry's first fully integrated Medicare ecosystem, enabling agencies and call centers to manage the entire sales process on a seamless platform — from lead flow to policy release.
Klick Health Acquires Ward6 Singapore
On March 24, medical technology company Klick Health acquired Ward6 Singapore. Through this acquisition, Klick will expand the scale of Singapore's largest independent life sciences advertising agency. Ward6 Singapore is renowned for its excellence in defining Healthcare Professional (HCP) marketing and medical communications. This acquisition strengthens Klick’s leadership and client portfolio in the Asia-Pacific (APAC) region, highlighting the ongoing expansion and growth of this award-winning global agency.
Virtual Digestive Health Provider Cylinder Acquires Dieta Health
On March 20, virtual digestive health provider Cylinder acquired Dieta Health, the creator of the world's first clinically validated AI-driven stool imaging application. This acquisition will advance Cylinder's goal of delivering more personalized digestive care and improving clinical outcomes. Dieta Health developed the world’s first mobile application with clinically validated AI stool image classification.
InformedDNA, a Genetics Expert Independent Provider Network Platform, Acquires Coriell Life Sciences
On March 19, InformedDNA, a genetics expert independent provider network platform, acquired Coriell Life Sciences. This strategic acquisition significantly expanded InformedDNA's capabilities, offering patients, providers, and payers broader genetic insights to make more personalized and data-driven treatment and medication decisions.
Medical device wholesaler Medline acquires Supira Medical
On March 19, medical device distributor Medline Medical acquired LeRay Medical, a developer of medical devices in the neurointerventional field. Medline's acquisition has drawn attention within the industry, not only marking a significant expansion of Medline Medical Group’s business scope but also introducing new variables to the development landscape of the entire medical device industry.
Artery Network/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/Fierce Health, etc.
Share
Like
Tap to view